Factor Xa inhibitors: all 607 studies that test it
Page 6 of 7. Open to participants first (111), then studies with results posted, then the rest; newest registration first within each.
- Dose-finding of Rivaroxaban in HemodialysisCompletedNCT02047006Phase 4
- Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With CancerCompletedNCT01989845Phase 4
- Prevention of Recurrence After Thrombolysis in Acute Iliofemoral Venous Thrombosis (PRAIS) StudyStatus unknownNCT01986192Not applicable
- A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy VolunteersCompletedNCT01954238Phase 1
- Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial FibrillationCompletedNCT01938248Phase 4
- Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular EventsStatus unknownNCT01924325Phase 2/3
- Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular EventsStatus unknownNCT01923818Phase 2/3
- Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard TabletCompletedNCT01853800Phase 1
- Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial FlutterCompletedNCT01839357Phase 3
- Antithrombotic Triple Therapy in HumansCompletedNCT01812200Phase 4
- A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male VolunteersCompletedNCT01765868Phase 1
- Anticoagulation With Rivaroxaban in Cardioversion -The ARC StudyCompletedNCT01747746Phase 4
- Thromboprophylaxis of Venous Thromboembolism in Acutely-ill Medical Inpatients With ThrombocytopeniaTerminatedNCT01727401Phase 4
- Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee ArthroplastyCompletedNCT01720108Phase 3
- Study in Cancer Patients With Central Line Associated Clots in the Upper Extremity Treated With Rivaroxaban (Catheter 2)CompletedNCT01708850Phase 4
- Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic DisorderCompletedNCT01707394Phase 1
- Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic EventsCompletedNCT01675076Phase 3
- A Study to Find Out How YM150 is Absorbed Into and Eliminated From the Body in Healthy Male SubjectsCompletedNCT01657981Phase 1
- A Study to Evaluate the Safety and Tolerability of YM150 in Healthy Caucasian and Japanese Male and Female Subjects, and to Assess the Effect That Gender May Have on Its Actions in the BodyCompletedNCT01655056Phase 1
- Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced ThrombocytopeniaTerminatedNCT01598168Phase 3
- Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) PatientsCompletedNCT01516840Phase 3
- Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) PatientsCompletedNCT01516814Phase 3
- A Study to Investigate the Plasma Concentration of YM150 After Repeated Administration to Elderly SubjectsCompletedNCT01514825Phase 1
- A Study to Investigate the Effect of YM150 on the Plasma Concentration of Digoxin in Healthy SubjectsCompletedNCT01514812Phase 1
- Reversal of the Antithrombotic Action of New Oral AnticoagulantsStatus unknownNCT01478282Phase 4
- Pharmacokinetics Study of Oral Rivaroxaban in Healthy ParticipantsCompletedNCT01464450Phase 1
- Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary InterventionCompletedNCT01442792Phase 2
- Food Effect Study For Apixaban Commercial Image TabletsCompletedNCT01437839Phase 1
- Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty SurgeryCompletedNCT01431456Phase 3
- To Evaluate Whether Acetyl Salicylic Acid (Aspirin) and Darexaban (YM150) Interact in Their EffectsCompletedNCT01424332Phase 1
- To Evaluate Whether Acetyl Salicylic Acid (Aspirin), the Combination of Aspirin and Clopidogrel and Darexaban (YM150) Interact in Their EffectsCompletedNCT01409616Phase 1
- To Evaluate Whether Naproxen and Darexaban (YM150) Interact in Their EffectsCompletedNCT01409603Phase 1
- To Evaluate if Multiple Doses of Rifampicin Change the Blood Concentration of YM150 (Darexaban)CompletedNCT01406002Phase 1
- To Evaluate if Multiple Doses of Ketoconazole Change the Blood Concentration of YM150 (Darexaban)CompletedNCT01405989Phase 1
- A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)CompletedNCT01379300Phase 1
- A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney FunctionCompletedNCT01309438Phase 1
- The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic SurgeryCompletedNCT01267305Not applicable
- Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thromboticsCompletedNCT01210755Phase 4
- Dose-confirmatory Bridging Study in Total Knee ReplacementCompletedNCT01206972Phase 3
- Dose-confirmatory Bridging Study in Total Hip ReplacementCompletedNCT01205932Phase 3
- Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous CatheterTerminatedNCT01195727Phase 1
- Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric SubjectsCompletedNCT01145859Phase 1
- Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild and Moderate Hepatic ImpairmentCompletedNCT01126086Phase 1
- A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150 TabletCompletedNCT01125670Phase 1
- A Study to Compare the Pharmacokinetics of YM150 Formulation-A and Formulation-BCompletedNCT01125657Phase 1
- "Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"CompletedNCT01121770Phase 1
- Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal ImpairmentCompletedNCT01120314Phase 1
- A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150CompletedNCT01118559Phase 1
- Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive StrategyCompletedNCT01076764Phase 3
- YM150 for Prevention of Venous Thromboembolism in Patients With Acute Medical IllnessCompletedNCT01028950Phase 3
- Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary SyndromesCompletedNCT00994292Phase 2
- BAY59-7939 Japanese in Atrial Fibrillation (2nd)CompletedNCT00973323Phase 2
- BAY59-7939 in Atrial Fibrillation Once Daily (OD)CompletedNCT00973245Phase 2
- A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal SurgeryCompletedNCT00942435Phase 3
- A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial FibrillationCompletedNCT00938730Phase 2
- Prevention of Venous Thromboembolism in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower ExtremitiesCompletedNCT00937911Phase 3
- Prevention of Recurrence of Venous Thromboembolism in Patients With a History of Venous ThromboembolismCompletedNCT00937820Phase 3
- Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism (VTE) in Medical Patients With Renal InsufficiencyTerminatedNCT00927602Phase 4
- Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement SurgeryCompletedNCT00917254Phase 2/3
- Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy VolunteersCompletedNCT00914641Phase 1
- Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement SurgeryCompletedNCT00913120Phase 2/3
- A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement SurgeryCompletedNCT00902928Phase 2/3
- Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in Bariatric Surgical PatientsCompletedNCT00894283Early Phase 1
- Prophylaxis of Thromboembolic Complications Trial: Thromboprophylaxis Needed in Below Knee Plaster Cast Immobilization for Ankle and Foot FracturesStatus unknownNCT00881088Phase 2/3
- ODiXahip - a Phase IIa Dose Escalating Proof of Principle TrialCompletedNCT00839826Phase 2
- Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)CompletedNCT00839163Phase 2
- BAY59-7939, Japanese Phase II in Atrial FibrillationTrial StatusCompletedNCT00779064Phase 2
- Prophylaxis Against DVTs After Primary Hip and Knee Replacement SurgeryStatus unknownNCT00767559Not applicable
- Safety and Efficacy of TAK-442 in Subjects With Acute Coronary SyndromesCompletedNCT00677053Phase 2
- Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of ProgressionWithdrawnNCT00659399Phase 1
- Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee ReplacementCompletedNCT00641732Phase 2
- Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)WithdrawnNCT00603824Phase 4
- A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement SurgeryCompletedNCT00595426Phase 2
- Phase IIa Venous Thromboembolism (VTE) Prevention Study In Total Knee Replacement (TKR)WithdrawnNCT00541320Phase 2
- Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU PatientsTerminatedNCT00493896Phase 3
- Pharmacokinetic Study of Fondaparinux in Outpatients With Renal DysfunctionWithdrawnNCT00483600Not applicable
- Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung CancerCompletedNCT00476216Phase 1
- Fondaparinux to Prevent Thrombotic Complications and Graft Failure in Patients Undergoing Coronary Artery Bypass Graft Surgery: The Fonda CABG StudyStatus unknownNCT00474591Phase 3
- Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial FibrillationCompletedNCT00448214Phase 2
- Investigation Into the Therapeutic Dosage of Fondaparinux Sodium, a Medication Used to Prevent Blood Clots in Morbidly Obese VolunteersCompletedNCT00436787Phase 2
- Fondaparinux as Monotherapy for DVT and/or Pulmonary EmbolismCompletedNCT00413504Not applicable
- Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee ReplacementCompletedNCT00408239Phase 2
- An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging StudyCompletedNCT00402467Phase 2
- Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip ReplacementCompletedNCT00398905Phase 2
- Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip ReplacementCompletedNCT00396786Phase 2
- Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein ThrombosisCompletedNCT00395772Phase 2
- Is Using Fondaparinux (Blood Thinner) to Treat Lung Clot Cheaper Than Traditional TherapyWithdrawnNCT00377091Phase 4
- Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.CompletedNCT00361894Phase 3
- Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)CompletedNCT00353678Phase 2
- Study to Determine Effective Dosing of Fondaparinux in Obese PersonsWithdrawnNCT00346879Phase 1
- Abdominal Surgery Study Of GSK576428 (Fondaparinux Sodium)In Japanese PatientsCompletedNCT00333021Phase 3
- Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip ReplacementCompletedNCT00332020Phase 3
- Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to EnoxaparinCompletedNCT00329628Phase 3
- ARIXTRA Local Study For Registration In China.CompletedNCT00328939Phase 3
- Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary SyndromeCompletedNCT00317395Phase 2
- Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee SurgeryCompletedNCT00306254Phase 2
- Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.TerminatedNCT00256100Not applicable
- Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT StudyCompletedNCT00252005Phase 2
- Michelangelo - Oasis 5CompletedNCT00139815Phase 3
- The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary InterventionCompletedNCT00133731Phase 2